Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 98.90B |
| Revenue (ttm) | 11.42B |
| Net Income (ttm) | 3.64B |
| Shares Out | 256.39M |
| EPS (ttm) | 14.07 |
| PE Ratio | 27.42 |
| Forward PE | 20.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,841,275 |
| Open | 381.91 |
| Previous Close | 381.87 |
| Day's Range | 379.72 - 387.48 |
| 52-Week Range | 362.50 - 519.88 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 493.64 (+27.97%) |
| Earnings Date | Nov 3, 2025 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $493.64, which is an increase of 27.97% from the latest price.
News
Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
Vertex Announces Key Advancements Across Kidney Portfolio
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated ki...
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bank of America Global Healthcare Conference 2025 September 23, 2025 3:10 AM EDT Company Participants Susie Lisa - Senior Vice President of Investor ...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (T...
Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality
Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal diab...
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey...
Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Reshma Kewalramani - CEO, President & Dir...
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
The Investment Committee discuss the latest Calls of the Day.
Vertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 11:00 AM EDT Company Participants Susie Lisa - Senior Vice President of Investor...
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases
LA JOLLA, Calif.--(BUSINESS WIRE)-- #ADC--Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals.
Vertex to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor...
Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More
This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals st...
Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet
A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly improve...
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)
The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF fra...
Weakness In Vertex Stock Seen As Buying Opportunity
Vertex Pharmaceuticals Inc. VRTX stock is falling on Tuesday after the company's pain data overshadowed strong second-quarter earnings.
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with...
Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Charles F. Wagner - Executive VP, COO & CFO Duncan McKechnie - Corpor...
Vertex tops estimates on cystic fibrosis treatment strength, new products
Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.
Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings
The biotechnology company's stock fell in post-market trading, after saying it would not progress a next-generation pain treatment into advanced testing.
Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.
Vertex to stop developing new painkiller as solo treatment after mid-stage study setback
Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo treatment after it failed to meet the main goal of a mid-stage trial.
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-rangi...